Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

Joshua D. Hansen, Matthew Correa, Mark A. Nagy, +25

Journal of Medicinal Chemistry

Hematological MalignancyNovel TherapyMedicineMalignant Blood DisorderImmunology +13

Discovery of (<i>R</i>)-7-Cyano-2,3,4,5-tetrahydro-1-(1<i>H</i>-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1<i>H</i>-1,4-benzodiazepine (BMS-214662), a Farnesyltransferase Inhibitor with Potent Preclinical Antitumor Activity

John T. Hunt, Charles Z. Ding, Roberta S. Batorsky, +20

Journal of Medicinal Chemistry

Medicinal Chemistry-1,4-Benzodiazepine FarnesyltransferaseBiochemistryChemoprevention StrategyMedicine +13

Development of Highly Potent Inhibitors of Ras Farnesyltransferase Possessing Cellular and<i>in Vivo</i>Activity

Katerina Leftheris, Toni Kline, Gregory D. Vite, +19

Journal of Medicinal Chemistry

Chemoprevention StrategyA1 Side ChainCellular PharmacologyChemical BiologyPharmaceutical Chemistry +15

Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF

Martin Decaris, Johanna Schaub, Chun Chen, +25

Respiratory Research

Design, Synthesis, and Anti-inflammatory Properties of Orally Active 4-(Phenylamino)-pyrrolo[2,1-<i>f</i>][1,2,4]triazine p38α Mitogen-Activated Protein Kinase Inhibitors

John Hynes, Alaric J. Dyckman, Shuqun Lin, +25

Journal of Medicinal Chemistry

Potent, Cell Active, Non-Thiol Tetrapeptide Inhibitors of Farnesyltransferase

John T. Hunt, Ving G. Lee, Katerina Leftheris, +6

Journal of Medicinal Chemistry

Bioorganic ChemistryPharmacotherapyChemical BiologyPharmaceutical ChemistryMolecular Pharmacology +14

<i>N</i>-Amination of Pyrrole and Indole Heterocycles with Monochloramine (NH₂Cl)

John Hynes, Wendel W. Doubleday, Alaric J. Dyckman, +4

The Journal of Organic Chemistry

Chemical EngineeringExcellent ReagentPyrrole-containing HeterocyclesEngineeringBiochemistry +9

5-Cyanopyrimidine Derivatives as a Novel Class of Potent, Selective, and Orally Active Inhibitors of p38α MAP Kinase

Chunjian Liu, Stephen T. Wrobleski, James C. Lin, +17

Journal of Medicinal Chemistry

5-Cyanopyrimidine DerivativesDrug TargetP38 InhibitorsCellular PharmacologyPharmacotherapy +17

The Discovery of a Dual TTK Protein Kinase/CDC2-Like Kinase (CLK2) Inhibitor for the Treatment of Triple Negative Breast Cancer Initiated from a Phenotypic Screen

Jennifer R. Riggs, Mark A. Nagy, Jan Elsner, +26

Journal of Medicinal Chemistry

Breast OncologyPharmaceutical ChemistryTumor BiologyMedicinal ChemistryOncology +16

Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-<i>N</i>-propylpyrrolo[1,2-<i>f</i>][1,2,4]triazine-6-carboxamide (BMS-582949), a Clinical p38α MAP Kinase Inhibitor for the Treatment of Inflammatory Diseases

Chunjian Liu, James C. Lin, Stephen T. Wrobleski, +25

Journal of Medicinal Chemistry

P38α Enzymatic AssayPharmacotherapyInflammatory ArthritisInflammationMolecular Pharmacology +16